Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$536.87 USD

536.87
1,976,220

+5.01 (0.94%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $536.96 +0.09 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance

by Zacks Equity Research

Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.

PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.

AMN Healthcare (AMN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Nurse and Allied Solutions segment drives AMN Healthcare's (AMN) third-quarter results.

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

We are encouraged to note that NuVasive (NUVA) witnessed solid revenue growth across its U.S. Spinal Hardware business in Q3.

Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet

by Zacks Equity Research

Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View

by Zacks Equity Research

IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.

CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.

Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2

by Zacks Equity Research

Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

by Zacks Equity Research

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

by Zacks Equity Research

Masimo (MASI) raises its 2019 product revenue guidance.

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

by Urmimala Biswas

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.

McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat

by Zacks Equity Research

McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.

Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.

Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat

by Zacks Equity Research

Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1

by Zacks Equity Research

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

by Zacks Equity Research

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3

by Zacks Equity Research

Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.

Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (TMO) Outperforming Other Medical Stocks This Year?

Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall

by Zacks Equity Research

Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.

Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View

by Zacks Equity Research

Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.

Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y

by Zacks Equity Research

Cerner (CERN) Q3 results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.